logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Table PDU-1. Prevalence of problem drug use at national level: Summary Table, 2002–06, rate per 1000 aged 15–64 [see all tables in this series...]

Part (i) Overall problem drug use

CountryNotesYearCentral rate/1000 ages 15–64Lower and Upper rates/1000 ages 15-64 [1]Estimated number of usersLower and upper bound of prevalence estimates [1]Target group, data sources and estimation methodsReference
Belgium::::::::
Bulgaria::::::::
Czech Republic120074.23.9-4.53090028900-32700Problem opioid and stimulant users. Low-threshold facilities. Treatment Multiplier.2
Denmark120057.57.1-8.02697925390-28568Drug abusers having a persistent use of illegal drugs including cannabis. The National Patient Register. National Register of Drug Abusers Undergoing Treatment. Capture-recapture.6
Germany2 *2006n.a.3.0-3.6182500167000-198000Problem opioid, cocaine and amphetamine users. National treatment statistics. Treatment Multiplier.:
Estonia:::::::
Ireland:::::::
Greece120072.72.4-3.12051618224-23181Problem drug users. Drug treatment data. Capture-recapture.3
Spain2 *2002n.a.7.1-9.9236359196928-275789Problem opioid and cocaine users. Treatment. Demographic method and combined methods.3
France120066.84.8-8.7263708189264-338169Problem opioid and stimulant users. Health and socio-economic indicators. Multivariate indicator method.2
Italy320078.68.1-9.0337187315788-352457Problem Stimulant and opiate users. Treatment data, Criminal Justice, Prison. Multivariate indicator method.25
Cyprus120073.72.9-4.719911591-2541Problem opioid and stimulant users. Treatment data. Truncated Poisson.5
Latvia*2006n.a.3.1-6.271914794-9588Problem drug users. Treatment data. Treatment Multiplier.4
Lithuania:::::::
Luxembourg:::::::
Hungary220053.52.8-4.22420419333-29075Problem drug users. Data from drug treatment and police records. Capture-recapture.2
Malta1 ; 520065.75.5-6.016061541-1685Problem drug users defined as daily heroin users. Treatment data. Capture-recapture.3
Netherlands:::::::
Austria120074.14.0-4.32317822198-24157(Poly-) drug use including opiates. Treatment and Police data. Capture-recapture.1
Poland2 ; 620054.23.7-4.7112500100000-125000Problem drug users. General population survey and Treatment data. Benchmark method.9
Portugal2 *2005n.a.4.3-7.44203730833-53240Problem drug users. Treatment and mortality data. Treatment multiplier and Outreach work teams multiplier.5
Romania:::::::
Slovenia20047.86.6-9.2106549078-12593Problem opioid and stimulant users. Treatment and police data. Capture-recapture.1
Slovakia120074.73.4-9.21788412794-34828Problem drug users. Low-threshold agencies. Multiplier method.6
Finland1 ; 420054.84.2-5.51660014500-19100Problem stimulant and opiate users. Hospital data, Criminal Justice, Infectious Diseases data. Capture-recapture. 7
Sweden220034.5n.a.25745n.a.Problem drug users. The Hospital Discharge Register.2
United Kingdom12006-079.99.7-10.3400469393247-417861Problem drug users. Treatment, population density, prison, drug-related deaths, drug offences, police, probation. Capture-recapture, multivariate indicator method.19
Croatia:::::::
Norway:::::::

Notes:

 n.a. = not available.                                 

 1 - Interval is a 95 % confidence interval.                                 

 2 - Confidence Interval not known.                                 

 3 - Interval is based on a sensitivity analysis.                                 

 4 - Finland: the original age range of study was 15–54, the rate was adjusted to ages 15–64.                                 

 5 - Malta: the original age range of the study is 12 to 64 years old.                                 

 6 - Poland: the original age range of the study refers to all ages.                                 

 * - The figure shown is based on average between the lower and upper bound of prevalence estimate.                                 

 For further details on methods and data sources/comments see Table PDU-102 and Table PDU-103.   

 See also ‘General notes for interpreting data’ on the Explanatory notes and help page                                 

Sources:

 For bibliographic references see Table PDU-0                                 

 2008 Reitox national reports - Fonte PDU template                                 

(see the help page for information about formats etc.)

Page last updated: Tuesday, 14 July 2009